Inspira Technologies Activates U.S. Based Consulting Firm for Strategic Initiatives

SEC Filing 6-K (0001213900-25-069677)

Inspira Technologies Oxy B.H.N. Ltd. announced the activation of a leading U.S. based consulting firm to accelerate high-impact execution across strategic expansion, partner engagement, and advanced structuring pathways. The consulting firm specializes in biotech and medtech companies, focusing on high-value strategic transactions, commercial growth acceleration, and enterprise value transformation. This move follows significant developments such as major purchase orders, strategic frameworks with government-linked health authorities, and clinical integration of Inspira’s ART100 system in Tier-1 U.S. hospitals. CEO Dagi Ben-Noon emphasized the need for coordinated, high-impact action to capitalize on current opportunities, with expected results surfacing in the near term. The consulting firm is facilitating targeted engagements with high-level stakeholders and evaluating scalable configurations to accelerate Inspira’s global footprint, aiming to reshape the company’s global market position and catalyze new layers of value creation in the second half of 2025.